|Mr. Mark D. McDonough||CEO, Pres & Director||528.85k||N/A||48|
|Mr. Scott R. Burell CPA||Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec.||364.6k||N/A||52|
|Dr. Karine Hovanes Ph.D., FACMG||VP of Scientific Advancement and Laboratory Director||N/A||N/A||N/A|
|Dr. Michael P. Strathmann Ph.D.||VP of R&D||N/A||N/A||N/A|
|Mr. Marc W. Booth||VP of Engineering||N/A||N/A||58|
CombiMatrix Corporation provides clinical molecular diagnostic laboratory services in the United States. The company focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It provides molecular diagnostic services primarily in the areas of reproductive health for the diagnosis of developmental disorders associated with intellectual disability, congenital anomalies, dysmorphic features, and autism spectrum disorders. The companys testing focuses on advanced technologies, including single nucleotide polymorphism, chromosomal microarray analysis, sequencing, fluorescent in situ hybridization, and high resolution karyotyping. It serves commercial insurance companies, healthcare institutions, government payors, and individuals. CombiMatrix Corporation was founded in 1995 and is headquartered in Irvine, California.
CombiMatrix Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.